Cargando…

Epicatechin oligomers longer than trimers have anti-cancer activities, but not the catechin counterparts

Since procyanidins (oligomeric catechin or epicatechin) were reported to exhibit health benefits, much attention has been paid to the synthesis of these compounds, especially those that are longer than trimers. In the present study, syntheses of cinnamtannin A3 (epicatechin pentamer), A4 (epicatechi...

Descripción completa

Detalles Bibliográficos
Autores principales: Takanashi, Kohki, Suda, Manato, Matsumoto, Kiriko, Ishihara, Chisato, Toda, Kazuya, Kawaguchi, Koichiro, Senga, Shogo, Kobayashi, Narumi, Ichikawa, Mikihiro, Katoh, Miyuki, Hattori, Yasunao, Kawahara, Sei-ichi, Umezawa, Koji, Fujii, Hiroshi, Makabe, Hidefumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552761/
https://www.ncbi.nlm.nih.gov/pubmed/28798415
http://dx.doi.org/10.1038/s41598-017-08059-x
_version_ 1783256511823216640
author Takanashi, Kohki
Suda, Manato
Matsumoto, Kiriko
Ishihara, Chisato
Toda, Kazuya
Kawaguchi, Koichiro
Senga, Shogo
Kobayashi, Narumi
Ichikawa, Mikihiro
Katoh, Miyuki
Hattori, Yasunao
Kawahara, Sei-ichi
Umezawa, Koji
Fujii, Hiroshi
Makabe, Hidefumi
author_facet Takanashi, Kohki
Suda, Manato
Matsumoto, Kiriko
Ishihara, Chisato
Toda, Kazuya
Kawaguchi, Koichiro
Senga, Shogo
Kobayashi, Narumi
Ichikawa, Mikihiro
Katoh, Miyuki
Hattori, Yasunao
Kawahara, Sei-ichi
Umezawa, Koji
Fujii, Hiroshi
Makabe, Hidefumi
author_sort Takanashi, Kohki
collection PubMed
description Since procyanidins (oligomeric catechin or epicatechin) were reported to exhibit health benefits, much attention has been paid to the synthesis of these compounds, especially those that are longer than trimers. In the present study, syntheses of cinnamtannin A3 (epicatechin pentamer), A4 (epicatechin hexamer), catechin tetramer, pentamer, arecatannin A2 (epicatechin-epicatechin-epicatechin-catechin) and A3 (epicatechin-epicatechin-epicatechin-epicatechin-catechin) were achieved. The key reaction was a Lewis acid mediated equimolar condensation. The antitumor effects of these synthesized compounds against a human prostate cancer cell line (PC-3) were investigated. Among the tested compounds, cinnamtannin A3, A4 and arecatannin A3, which possess epicatechin oligomers longer than tetramers as the basic scaffold, showed significant activities for suppression of cell growth, invasion and FABP5 (fatty acid-binding protein 5) gene expression. Effects on cell cycle distribution showed that cell cycle arrest in the G2 phase was induced. Furthermore, these epicatechin oligomers suppressed significantly the expression of the cancer-promoting gene, FABP5, which is related to cell proliferation and metastasis in various cancer cells. Interestingly, the suppressive activities were associated with the degree of oligomerization of epicatechin. Thus, synthetic studies clearly demonstrate that epicatechin oligomers longer than trimers have significant anti-tumorigenic activities, but not the catechin counterparts.
format Online
Article
Text
id pubmed-5552761
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-55527612017-08-14 Epicatechin oligomers longer than trimers have anti-cancer activities, but not the catechin counterparts Takanashi, Kohki Suda, Manato Matsumoto, Kiriko Ishihara, Chisato Toda, Kazuya Kawaguchi, Koichiro Senga, Shogo Kobayashi, Narumi Ichikawa, Mikihiro Katoh, Miyuki Hattori, Yasunao Kawahara, Sei-ichi Umezawa, Koji Fujii, Hiroshi Makabe, Hidefumi Sci Rep Article Since procyanidins (oligomeric catechin or epicatechin) were reported to exhibit health benefits, much attention has been paid to the synthesis of these compounds, especially those that are longer than trimers. In the present study, syntheses of cinnamtannin A3 (epicatechin pentamer), A4 (epicatechin hexamer), catechin tetramer, pentamer, arecatannin A2 (epicatechin-epicatechin-epicatechin-catechin) and A3 (epicatechin-epicatechin-epicatechin-epicatechin-catechin) were achieved. The key reaction was a Lewis acid mediated equimolar condensation. The antitumor effects of these synthesized compounds against a human prostate cancer cell line (PC-3) were investigated. Among the tested compounds, cinnamtannin A3, A4 and arecatannin A3, which possess epicatechin oligomers longer than tetramers as the basic scaffold, showed significant activities for suppression of cell growth, invasion and FABP5 (fatty acid-binding protein 5) gene expression. Effects on cell cycle distribution showed that cell cycle arrest in the G2 phase was induced. Furthermore, these epicatechin oligomers suppressed significantly the expression of the cancer-promoting gene, FABP5, which is related to cell proliferation and metastasis in various cancer cells. Interestingly, the suppressive activities were associated with the degree of oligomerization of epicatechin. Thus, synthetic studies clearly demonstrate that epicatechin oligomers longer than trimers have significant anti-tumorigenic activities, but not the catechin counterparts. Nature Publishing Group UK 2017-08-10 /pmc/articles/PMC5552761/ /pubmed/28798415 http://dx.doi.org/10.1038/s41598-017-08059-x Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Takanashi, Kohki
Suda, Manato
Matsumoto, Kiriko
Ishihara, Chisato
Toda, Kazuya
Kawaguchi, Koichiro
Senga, Shogo
Kobayashi, Narumi
Ichikawa, Mikihiro
Katoh, Miyuki
Hattori, Yasunao
Kawahara, Sei-ichi
Umezawa, Koji
Fujii, Hiroshi
Makabe, Hidefumi
Epicatechin oligomers longer than trimers have anti-cancer activities, but not the catechin counterparts
title Epicatechin oligomers longer than trimers have anti-cancer activities, but not the catechin counterparts
title_full Epicatechin oligomers longer than trimers have anti-cancer activities, but not the catechin counterparts
title_fullStr Epicatechin oligomers longer than trimers have anti-cancer activities, but not the catechin counterparts
title_full_unstemmed Epicatechin oligomers longer than trimers have anti-cancer activities, but not the catechin counterparts
title_short Epicatechin oligomers longer than trimers have anti-cancer activities, but not the catechin counterparts
title_sort epicatechin oligomers longer than trimers have anti-cancer activities, but not the catechin counterparts
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552761/
https://www.ncbi.nlm.nih.gov/pubmed/28798415
http://dx.doi.org/10.1038/s41598-017-08059-x
work_keys_str_mv AT takanashikohki epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts
AT sudamanato epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts
AT matsumotokiriko epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts
AT ishiharachisato epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts
AT todakazuya epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts
AT kawaguchikoichiro epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts
AT sengashogo epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts
AT kobayashinarumi epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts
AT ichikawamikihiro epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts
AT katohmiyuki epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts
AT hattoriyasunao epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts
AT kawaharaseiichi epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts
AT umezawakoji epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts
AT fujiihiroshi epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts
AT makabehidefumi epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts